Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19037381 | 0.81 | KMT2A (0.48) | KMT2APABPC1KDM4EHSP90AA1ACHE | |
| Hydrochloric Acid SCHEMBL19031290 | 0.79 | KMT2A (0.47) | KMT2APABPC1KDM4EHSP90AA1ACHE | |
| SCHEMBL12534300 | 0.77 | KMT2A (0.50) | KMT2APABPC1KDM4EHSP90AA1ACHE | |
| SCHEMBL19037385 | 0.77 | KMT2A (0.45) | KMT2APABPC1KDM4EHSP90AA1ACHE | |
| SCHEMBL3771803 | 0.77 | KMT2A (0.45) | KMT2APABPC1KDM4EHSP90AA1ACHE | |
| Bromide SCHEMBL9080240 | 0.76 | KMT2A (0.53) | KMT2APABPC1KDM4EHSP90AA1ACHE | |
| Hydrochloric Acid SCHEMBL5848674 | 0.76 | HSP90AA1 (0.50) | KMT2AKDM4EHSP90AA1ACHEPOLB | |
| SCHEMBL4232151 | 0.74 | KMT2A (0.47) | KMT2AHSP90AA1ACHEPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL624259 | 0.72 | KMT2A (0.46) | KMT2AHSP90AA1ACHEPOLBALDH1A1 | |
| Bromide SCHEMBL344154 | 0.72 | KMT2A (0.50) | KMT2AKDM4EHSP90AA1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748452-B2 | Indolizine derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | disclosed |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, INMT, PON1 | KMT2A 2454/4885PABPC1 4714/4885KDM4E 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.